Kalaris Therapeutics, Inc. Common Stock KLRS Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $98.05M+5,883% | $1.64M-98.2% | $90.12M-15.1% | $106.09M-47.4% | ||
| $19.93M— | $0-100% | $93.82M-26.5% | $127.7M+175% | ||
| $499K— | $0-100% | $852K0.0% | $852K0.0% | ||
| $6.45M+149% | $2.59M-83.5% | $15.68M— | —— | ||
| $118.81M+4,459% | $2.61M-98.6% | $187.64M-22.8% | $243.05M-4.1% | ||
| $1.48M— | $0-100% | $2.19M-93.1% | $31.63M+6.4% | ||
| $953K+132% | $410K+236% | $122K-80.1% | $612K-44.5% | ||
| $121.74M+1,876% | $6.16M-96.8% | $190.8M-31.1% | $277.08M-3.3% | ||
| $1.28M-17.9% | $1.56M-76.9% | $6.76M+125% | $3M-64.1% | ||
| $316K— | $0-100% | $10.78M+50.5% | $7.17M+8.7% | ||
| $9.71M-60.7% | $24.7M-12.9% | $28.37M+16.6% | $24.34M-35.7% | ||
| $1.13M— | $0-100% | $16.65M-41.0% | $28.22M+20.2% | ||
| $1.45M— | —— | $27.43M-22.5% | $35.39M— | ||
| $42.92M-24.4% | $56.78M+26.1% | $45.02M-14.4% | $52.56M-14.3% | ||
| $2K— | $0— | $0-100% | $9K+28.6% | ||
| $238.81M+1,097% | $19.95M-97.5% | $802.04M+16.1% | $690.75M+32.2% | ||
| -$160M-37.3% | -$116.56M+82.2% | -$656.19M-40.9% | -$465.78M-56.8% | ||
| $6K— | $0+100% | -$62K+86.8% | -$468K-202% | ||
| $78.81M+182% | -$96.62M-115% | -$45.02M-120% | $224.52M-0.3% | ||
| $121.74M+1,876% | $6.16M-96.8% | $190.8M-31.1% | $277.08M-3.3% | ||
| $953K+132% | $410K+236% | $122K-80.1% | $612K-44.5% | ||
| $1.48M— | $0-100% | $2.19M-93.1% | $31.63M+6.4% | ||
| $1.48M— | $0-100% | $2.19M-93.1% | $31.63M+6.4% | ||
| $953K+132% | $410K+236% | $122K-80.1% | $612K-44.5% | ||
| $19.93M— | $0-100% | $93.82M-26.5% | $127.7M+175% | ||
| $1.48M— | $0-100% | $2.19M-93.1% | $31.63M+6.4% | ||
| $953K+132% | $410K+236% | $122K-80.1% | $612K-44.5% | ||
| $8.12M+270% | $2.2M— | —— | —— | ||
| $32.08M0.0% | $32.08M— | —— | —— | ||
| $1.45M— | —— | $27.43M-22.5% | $35.39M+17.7% | ||
| $2K— | $0— | $0-100% | $9K+28.6% | ||
| $0— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Kalaris Therapeutics, Inc. Common Stock's total assets?
- Kalaris Therapeutics, Inc. Common Stock (KLRS) holds $109.8M in total assets, up 6.5% year over year.
- How much debt does Kalaris Therapeutics, Inc. Common Stock have?
- Kalaris Therapeutics, Inc. Common Stock carries $1.4M in total debt against $68.6M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Kalaris Therapeutics, Inc. Common Stock have?
- Kalaris Therapeutics, Inc. Common Stock holds $34.4M in cash and equivalents.
- Can Kalaris Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 12.19 — current assets exceed current liabilities.
- Where does Kalaris Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.